268 related articles for article (PubMed ID: 15291352)
1. Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies.
Robak T; Smolewski P; Urbanska-Rys H; Gora-Tybor J; Blonski JZ; Kasznicki M
Leuk Lymphoma; 2004 May; 45(5):937-44. PubMed ID: 15291352
[TBL] [Abstract][Full Text] [Related]
2. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma.
Robak T; Smolewski P; Cebula B; Szmigielska-Kaplon A; Chojnowski K; Blonski JZ
Cancer; 2006 Oct; 107(7):1542-50. PubMed ID: 16948126
[TBL] [Abstract][Full Text] [Related]
3. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
4. Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies.
Robak T; Góra-Tybor J; Lech-Marańda E; Błoński JZ; Kasznicki M
Eur J Haematol; 2001 Mar; 66(3):188-94. PubMed ID: 11350487
[TBL] [Abstract][Full Text] [Related]
5. Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia.
Robak T; Smolewski P; Cebula B; Grzybowska-Izydorczyk O; Błoński JZ
Eur J Haematol; 2007 Aug; 79(2):107-13. PubMed ID: 17635235
[TBL] [Abstract][Full Text] [Related]
6. Bendamustine mitoxantrone and rituximab (BMR): a new effective regimen for refractory or relapsed indolent lymphomas.
Weide R; Heymanns J; Gores A; Köppler H
Leuk Lymphoma; 2002 Feb; 43(2):327-31. PubMed ID: 11999564
[TBL] [Abstract][Full Text] [Related]
7. Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia.
Robak T; Błoński JZ; Kasznicki M; Góra-Tybor J; Dwilewicz-Trojaczek J; Stella-Hołowiecka B; Wołowiec D
Hematol J; 2002; 3(5):244-50. PubMed ID: 12391542
[TBL] [Abstract][Full Text] [Related]
8. Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
Nagai H; Ogura M; Kusumoto S; Takahashi N; Yamaguchi M; Takayama N; Kinoshita T; Motoji T; Ohyashiki K; Kosugi H; Matsuda S; Ohnishi K; Omachi K; Hotta T
Eur J Haematol; 2011 Feb; 86(2):117-23. PubMed ID: 21070370
[TBL] [Abstract][Full Text] [Related]
9. Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma.
Robak T; Lech-Maranda E; Janus A; Blonski J; Wierzbowska A; Gora-Tybor J
Leuk Lymphoma; 2007 Jun; 48(6):1092-101. PubMed ID: 17577772
[TBL] [Abstract][Full Text] [Related]
10. Re-treatment with cladribine-based regimens in relapsed patients with B-cell chronic lymphocytic leukemia. Efficacy and toxicity in comparison with previous treatment.
Robak T; Boński JZ; Kasznicki M; Góra-Tybor J; Hellmann A; Konopka L; Dmoszyńska A; Dwilewicz-Trojaczek J; Wołowiec D;
Eur J Haematol; 2002 Jul; 69(1):27-36. PubMed ID: 12270059
[TBL] [Abstract][Full Text] [Related]
11. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
12. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
Weide R; Hess G; Köppler H; Heymanns J; Thomalla J; Aldaoud A; Losem C; Schmitz S; Haak U; Huber C; Unterhalt M; Hiddemann W; Dreyling M;
Leuk Lymphoma; 2007 Jul; 48(7):1299-306. PubMed ID: 17613757
[TBL] [Abstract][Full Text] [Related]
13. High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias.
Betticher DC; Fey MF; von Rohr A; Tobler A; Jenzer H; Gratwohl A; Lohri A; Pugin P; Hess U; Pagani O
Ann Oncol; 1994 Jan; 5(1):57-64. PubMed ID: 7909685
[TBL] [Abstract][Full Text] [Related]
14. 2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders.
Rondelli D; Lauria F; Zinzani PL; Raspadori D; Ventura MA; Galieni P; Birtolo S; Forconi F; Algeri R; Tura S
Eur J Haematol; 1997 Jan; 58(1):46-50. PubMed ID: 9020373
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
16. Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
Hendry L; Bowen A; Matutes E; Swansbury J; Catovsky D
Leuk Lymphoma; 2004 May; 45(5):945-50. PubMed ID: 15291353
[TBL] [Abstract][Full Text] [Related]
17. Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia.
Robak T; Błoński JZ; Kasznicki M; Góra-Tybor I; Dwilewicz-Trojaczek J; Boguradzki P; Konopka L; Ceglarek B; Sułek J; Kuliczkowski K; Wołowiec D; Stella-Hołowiecka B; Skotnicki AB; Nowak W; Moskwa-Sroka B; Dmoszyńska A; Calbecka M
Leukemia; 2001 Oct; 15(10):1510-6. PubMed ID: 11587207
[TBL] [Abstract][Full Text] [Related]
18. Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.
Lin TS; Blum KA; Fischer DB; Mitchell SM; Ruppert AS; Porcu P; Kraut EH; Baiocchi RA; Moran ME; Johnson AJ; Schaaf LJ; Grever MR; Byrd JC
J Clin Oncol; 2010 Jan; 28(3):418-23. PubMed ID: 20008633
[TBL] [Abstract][Full Text] [Related]
19. High incidence of complications after 2-chloro-2'-deoxyadenosine combined with cyclophosphamide in patients with advanced lymphoproliferative malignancies.
Van Den Neste E; Michaux L; Layios N; Costantini S; Francart J; Lambert C; Sonet A; André M; Robert A; Ferrant A
Ann Hematol; 2004 Jun; 83(6):356-63. PubMed ID: 15024607
[TBL] [Abstract][Full Text] [Related]
20. Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group.
Inwards DJ; Fishkin PA; Hillman DW; Brown DW; Ansell SM; Kurtin PJ; Fonseca R; Morton RF; Veeder MH; Witzig TE
Cancer; 2008 Jul; 113(1):108-16. PubMed ID: 18470909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
